全文获取类型
收费全文 | 1512篇 |
免费 | 61篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 38篇 |
妇产科学 | 8篇 |
基础医学 | 202篇 |
口腔科学 | 48篇 |
临床医学 | 95篇 |
内科学 | 373篇 |
皮肤病学 | 29篇 |
神经病学 | 99篇 |
特种医学 | 113篇 |
外科学 | 182篇 |
综合类 | 22篇 |
预防医学 | 79篇 |
眼科学 | 11篇 |
药学 | 129篇 |
中国医学 | 2篇 |
肿瘤学 | 143篇 |
出版年
2022年 | 15篇 |
2021年 | 38篇 |
2020年 | 14篇 |
2019年 | 29篇 |
2018年 | 36篇 |
2017年 | 19篇 |
2016年 | 26篇 |
2015年 | 22篇 |
2014年 | 55篇 |
2013年 | 60篇 |
2012年 | 69篇 |
2011年 | 65篇 |
2010年 | 49篇 |
2009年 | 60篇 |
2008年 | 54篇 |
2007年 | 68篇 |
2006年 | 60篇 |
2005年 | 54篇 |
2004年 | 38篇 |
2003年 | 47篇 |
2002年 | 46篇 |
2001年 | 37篇 |
2000年 | 38篇 |
1999年 | 32篇 |
1998年 | 25篇 |
1997年 | 25篇 |
1996年 | 26篇 |
1995年 | 26篇 |
1994年 | 16篇 |
1993年 | 11篇 |
1992年 | 27篇 |
1991年 | 27篇 |
1990年 | 28篇 |
1989年 | 42篇 |
1988年 | 16篇 |
1987年 | 34篇 |
1986年 | 26篇 |
1985年 | 30篇 |
1984年 | 18篇 |
1983年 | 16篇 |
1982年 | 6篇 |
1980年 | 16篇 |
1979年 | 25篇 |
1978年 | 14篇 |
1977年 | 13篇 |
1975年 | 10篇 |
1973年 | 8篇 |
1972年 | 11篇 |
1971年 | 6篇 |
1967年 | 6篇 |
排序方式: 共有1579条查询结果,搜索用时 46 毫秒
1.
M Strolin Benedetti E Pianezzola D Fraier M G Castelli P Dostert 《Xenobiotica; the fate of foreign compounds in biological systems》1991,21(4):473-480
1. The (13S)-dihydro derivative of idarubicin, (13S)-idarubicinol, is the major urinary metabolite of idarubicin in humans. Idarubicinol epimers were quantified by h.p.l.c. in urine from rats, mice, rabbits, dogs and man after i.v. administration of idarubicin, and in man after oral dosing. The (13R)- and (13S)-epimers of idarubicinol were determined in rat bile. 2. After i.v. injection of idarubicin. (13R)-idarubicinol was not detectable in mice and rabbit urine and no more than 0.5% of the dose was present in the urine of other species. In man, the proportion of (13R)-idarubicinol in total idarubicinol was similar after i.v. (4.1%) and oral (3.8-5.0%) administration of idarubicin; the same applies to rat bile and urine. 3. Reduction of idarubicin in vivo is dependent upon ketone reductases, and proceeds more stereoselectively than that of most ketones giving rise to the (13S)-epimer almost exclusively. The high stereospecificity in idarubicin reduction might result from chiral induction due to the presence of asymmetric centres near to the carbonyl group in idarubicin. 相似文献
2.
3.
A Bortolotti D Castelli D Verotta M Bonati 《European journal of drug metabolism and pharmacokinetics》1989,14(2):145-151
The pharmacokinetic and pharmacodynamic profiles of metoprolol were studied in adult male rabbits given 3.2 mg/kg i.v. before and during liver failure. The partition of metoprolol between blood cells and plasma averaged 1.14 in both conditions. Plasma protein binding, concentration-independent, was 32% and 17% in normal and pathological status, respectively. With normal liver function the terminal elimination half-life for the drug was 0.54-0.96 h, rising to 1.0-2.1 h in liver failure. Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1). Liver impairment did not affect the volume of distribution of the central compartment, the steady-state volume of distribution and the other intercompartmental rate constants. Although metoprolol was eliminated in the urine, the amount excreted was low (1.5% of the administered dose) in both conditions. The pharmacokinetic model was extended by an 'effect compartment', which has no influence on the predetermined mass of drug in the body, to analyse the relationship between heart rate fall and changes in metoprolol plasma concentrations. After drug administration, heart rate fell rapidly about 90 beats in both states. The mean unbound plasma concentration producing 50% of this reduction was double during liver failure compared to normal condition (0.03 vs 0.07 mg/l), but the temporal aspects of drug equilibration with site of action were similar. 相似文献
4.
5.
Endovascular repair for concomitant multilevel aortic disease. 总被引:2,自引:0,他引:2
Patrizio Castelli Roberto Caronno Gabriele Piffaretti Matteo Tozzi Chiara Lomazzi Domenico Laganà Gianpaolo Carrafiello Salvatore Cuffari 《European journal of cardio-thoracic surgery》2005,28(3):478-482
OBJECTIVE: Patients with multilevel aortic disease represent a small subgroup with the need for extensive surgical treatment at considerable risk. We present our experience of endovascular exclusion for simultaneous thoracic and abdominal aortic disease in four patients. METHODS: Between January 2002 and January 2005, four patients underwent endovascular repair for simultaneous thoracic and abdominal aortic disease. Mean age was 69+/-10 years (range, 60-81). Thoracic lesions included penetrating aortic ulcer (n=2, ruptured=1), atherosclerotic aneurysm (n=1), and chronic type B dissection (n=1). Abdominal aortic disease included atherosclerotic infrarenal (n=3) and juxtarenal (n=1) aortic aneurysms. Thoracic aortic stent-grafts had been the following: Excluder/TAG (n=3) or Talent (n=1) straight tube devices. Abdominal aortic stent-grafts used were as following: Excluder (n=3) or Zenith (n=1). All patients were followed-up with CT-angiography and chest X-rays 1, 4, 12 months after the procedure, and once per year thereafter. RESULTS: Stent-graft deployment was technically successful in all cases. Intraoperative mortality was not observed. Mean procedure time was 94+/-34 min (range, 70-145). Early postoperative complications occurred in one patient that developed acute renal failure but dialysis was not required. Mean hospitalisation was 8+/-5 days (range, 4-15). Late death occurred in one patient for an undetected ruptured thoracic type 1 endoleak. All three survivors are currently well 16.5 months (range, 3-36) after surgery. No neurological complications developed. CONCLUSION: Simultaneous abdominal and thoracic endovascular repair for multilevel aortic disease is feasible and could be a viable alternative in high-risk patients, who otherwise may not be suitable candidates for conventional repair. 相似文献
6.
D. M. F. Edwards C. Pellizzoni H. P. Breuel A. Berardi M. G. Castelli E. Frigerio I. Poggesi M. Rocchetti A. Dubini M. Strolin Benedetti 《Biopharmaceutics & drug disposition》1995,16(6):443-460
The pharmacokinetics of reboxetine, a new antidepressant agent, were found to be close to linear in a crossover study comparing administration of single 2, 3, 4 and 5 mg capsule doses in 15 healthy male volunteers, and in the same study the capsules were bioequivalent to the proposed therapeutic tablet formulation (4mg). Kinetic analysis was based on HPLC assay of reboxetine in plasma and urine collected up to 72 h after each administration. Plasma levels indicated a rapid absorption (tmax?2h) and an elimination half-life of about 13 h. Clearance and volume of distribution were modest (ratios to bioavailability: CL/F?29 mL min?1; Vz/F?32L); urinary excretion was ~9% of dose, corresponding to a renal clearance of only 3 mL min?1 (a value consistent with the rate of glomerular filtration of unbound drug). In vitro, binding to plasma proteins, estimated from radioactivity levels following dialysis of 14C-labelled reboxetine, appeared to be dominated by α1-acid glycoprotein without marked saturation up to plasma concentrations of over 500 ng mL?1 (2.8–3.1% unbound with human plasma from three additional volunteers; 1.8–2.0% for 2gL?1 orosomucoid α1-acid glycoprotein, and 46.4–47.4% for 40 gL?1 albumin), whilst the mean Cmax in the current study was much lower (164 ng mL?1 after a 5 mg dose). 相似文献
7.
Caporale CM Capasso M Lucani M Gandolfi P De Angelis MV Di Muzio A Caporale V Uncini A . 《Journal of the peripheral nervous system : JPNS》2004,9(2):114-115
Campylobacter jejuni (C. jejunj) infection is the most common antecedent in the axonal variant of Guillain‐Barré syndrome (GBS). Antibodies against nerve gangliosides found in GBS patients recognize cross‐reactive epitopes in the lipopolysaccharide (LPS) of C. jejuni. This led to the molecular mimicry hypothesis of GBS. We immunized eleven rabbits with a LPS extracted from HS:19 C. jejuni strain isolated from a patient with GBS and complete Freund's adjuvant (CFA)(group I). In a second experiment we immunized seven rabbits with LPS, CFA and keyhole limpet hemocyanin (KLH)(group II). All group I rabbits developed high titers of anti‐LPS, anti‐GM1, anti‐GD1b antibodies and lower titers of anti‐GD1a. One rabbit, 50 days after initial inoculation, showed tremor and weakness. All rabbits of group II developed high titres of antiganglioside antibodies and six animals showed weakness 59–113 days after initial inoculation. Two rabbits died. Pathology showed mild to moderate, tendentially grouped, axonal degeneration in sciatic nerves of four out of five animals. Control rabbits of group I (immunized with CFA only) did not develop antibodies, controls of group II (immunized with CFA + KLH) developed low titers of IgG anti‐GM1. None developed neurological signs or showed axonal degeneration. C. jejuni LPS is a potent B‐cell stimulator capable to induce a strong antiganglioside response in rabbits. However, to induce the neuropathy is crucial to employ KLH, a glycoprotein known to stimulate both humoral and cellular responses. This animal model reproduces the pathogenetic process hypothesized in axonal GBS with antiganglioside antibodies post C. jejuni infection. 相似文献
8.
9.
10.
William E. Gillies FRACS FRACO FRCS Anne MV Brooks MD PhD FRACS FRACO FRACP 《Clinical & experimental ophthalmology》1996,24(3):169-187
Background: We have investigated the vascular perfusion of a wide variety of conditions of the anterior segment using fluorescein angiography.
Methods: The conditions were classified and findings reported according to the system set out below. Patients underwent full ocular examination. Fluorescein angiography of the anterior segment was carried out when indicated to investigate iris atrophy and neovascularisation. Specular microscopy of the corneal endothelium was used to detect changes in this tissue.
Results: The hypoperfusion was variable in degree and accompanied by varying degrees of iris hypoplasia and atrophy with neovascularisation. The degree of neovascularisation depended upon its rapidity of development, the pre-existing state of vascular perfusion and the underlying pathological condition.
Conclusions: Hypoperfusion with resultant ischaemia and neovascularisation is common in conditions of the anterior segment. An understanding of the changes is valuable in treating many conditions affecting the anterior segment. The changes observed may also occur elsewhere in the physical system and may be a significant part of the ageing process, either as scattered, disparate processes or as part of a general disease process. 相似文献
Methods: The conditions were classified and findings reported according to the system set out below. Patients underwent full ocular examination. Fluorescein angiography of the anterior segment was carried out when indicated to investigate iris atrophy and neovascularisation. Specular microscopy of the corneal endothelium was used to detect changes in this tissue.
Results: The hypoperfusion was variable in degree and accompanied by varying degrees of iris hypoplasia and atrophy with neovascularisation. The degree of neovascularisation depended upon its rapidity of development, the pre-existing state of vascular perfusion and the underlying pathological condition.
Conclusions: Hypoperfusion with resultant ischaemia and neovascularisation is common in conditions of the anterior segment. An understanding of the changes is valuable in treating many conditions affecting the anterior segment. The changes observed may also occur elsewhere in the physical system and may be a significant part of the ageing process, either as scattered, disparate processes or as part of a general disease process. 相似文献